French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a deal with an equity value of $2.9 billion. The deal will allow Sanofi to add to its portfolio, TZIELD, which was approved in the U.S. last year as the first disease-modifying treatment for the delay of Stage 3 type 1 diabetes (T1D). Provention announced late last year a deal with Sanofi to co-promote the treatment in the U.S..
Source: finance.yahoo.com
Related posts:
Former Theranos Chemist Says Elizabeth Holmes Was Aware of Testing Failures
Should You Buy Stocks With the S&P 500 Near Record Highs? Warren Buffett Has Brilliant Advice fo...
Costco Is Up 32% in 2024: Could the Stock-Split Candidate Hit $1,000 per Share by the End of the Yea...
Jeremy Grantham, Michael Burry warn of another market plunge. Avoid this beginner mistake when the s...
Coca-Cola Is a Rock-Solid Dividend Stock, but So Are These High-Yield Stocks That Are Down Between 1...